Kala Bio (KALA): CHIEF BUSINESS OFFICER sold, ~$18K

~$18K
Approx. value · 4,511 sh @ $4.01: 63K
Holds after · shares reported

Traded: Jun 24, 2025
Filed: Jun 27, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Jun 3, 2025Insider · 5 peopleInsiders: 5 sales (~$80K)
Jun 24, 2025 · this disclosureInsiderOfficer sold ~$18K of KALA shares in the open market

What came next

Jun 24, 2025Insider · 4 peopleInsiders: 4 sales (~$105K)
Sep 28, 2025Company filing · Form 8-K · Restructuring, Other newsAnnounced job cuts, closures or a restructuring, and reported other company news“On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options.”
Sep 28, 2025Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member“On October 2, 2025, the Company entered into retention agreements (each, a “Retention Agreement”) with Todd Bazemore, the Company’s President and Chief Executive Officer, Mary Reumuth, the Company’s Chief Financial Officer, and Kim Brazzell, Ph.D., the Company’s Head of Research and Development and Chief Medical Officer.”
Sep 29, 2025Company filing · Form 8-K · Debt acceleratedHad a debt or obligation accelerated“On September 29, 2025, KALA BIO, Inc. (the “Company”) received a written notice (the “Notice”) of event of default from Oxford Finance LLC (“Oxford”) with respect to that certain Loan and Security Agreement, dated as of May 4, 2021 (as amended, the “Loan Agreement”), by and among the Company, Combangio, Inc. and Oxford, as lender and collateral agent.”
Oct 19, 2025Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“On October 19, 2025, in connection with the Reduction, the Board terminated without cause the employment of Todd Bazemore, the Company’s President and Chief Executive Officer, effective immediately.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Kala Bio

OQRO holds no insider, Congress, fund or contract record for Kala Bio dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KALA page.

Other recent filings by Darius Kharabi, CHIEF BUSINESS OFFICER

The full history of Darius Kharabi, CHIEF BUSINESS OFFICER is on the profile page.

Other disclosures at Kala Bio

Everything OQRO holds on this company is on its KALA page.

Kala Bio (KALA)CHIEF BUSINESS OFFICER sold ~$18K